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1. Introduction
Wilson et al. [1] investigated the progression of glioblastoma (Grade 4) at the cellular level
and showed that cells from tumors of 4 cm or greater in diameter on diagnostic imaging are
considered to be present in both normal and affected brain tissues, with a distribution of
92% of tumor cells in the tumor bulk, 6% in areas within a 2-cm margin around the tumor,
and 1.8% within an additional 2-cm area surrounding this margin. The majority of recurrent
malignant gliomas develop in this marginal area, and therefore, controlling infiltrating cells
in this region while protecting normal brain cells is critical to inhibit tumor recurrence.
In photodynamic therapy (PDT), a photosensitizer taken up in tumor tissues and neovascular‐
ized tumor vessels is administered to cancer patients. Tumor tissues are then later irradiated
using a laser to induce a photochemical reaction in the photosensitizer, thereby selectively
causing tumor cell apoptosis and necrosis. This tumor cell apoptosis and necrosis result from
the strong oxidative effect of singlet oxygen (active oxygen) produced by the photochemical re‐
action in the photosensitizer, induced by a laser at a specific wavelength [2].
We previously reported that PDT using talaporfin sodium (TS), a second-generation photo‐
sensitizer, induced tumor coagulation necrosis and tumor cell-selective apoptosis in rats in
which C6 glioma cells had been transplanted into the brain [3]. In the present study, we
evaluated the safety and efficacy of PDT in areas with tumor invasion following tumor re‐
moval in patients with malignant glioma.
2. Materials
Eligible subjects were patients with a first time diagnosis of adult intracranial malignant
glioma (Grade 3 or 4) based on preoperative diagnostic imaging and with a tumor bulk adja‐
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cent to the eloquent areas of the brain associated with language, motor, sensation and vi‐
sion, for which a wide resection of the tumor much larger than the tumor bulk was
impossible. Selective treatment of the infiltrating tumor cells by PDT was considered neces‐
sary because of tumor invasion into the eloquent areas, despite the fact that the tumor bulk
had been removed as extensively as possible. PDT was performed after a rapid intraopera‐
tive pathological diagnosis confirmed malignant glioma. We excluded patients who had re‐
ceived radiotherapy or chemotherapy within 3 weeks prior to the surgery, patients with
bleeding or abnormal coagulation test results, and patients with porphyria or porphyrin hy‐
persensitivity. This clinical study was approved by the Institutional Review Board of our in‐
stitution. All subjects provided written informed consent. The subjects were consecutive 8
patients (7 men and 1 woman) treated at our hospital between May 2006 and Mar 2009 and
aged 48 to 82 years (median, 58 years). The tumors were localized in the frontal lobe in 4
patients, temporal lobe in 2 patients, insular gyrus in 1 patient and parietal lobe in 1 patient.
Preoperative Karnofsky Performance Scale (KPS) was 50 to 80 (median 60). The extent of tu‐
mor resection was subtotal in 7 patients and partial in 1 patient. The final pathological diag‐
nosis was Grade 3 in 3 patients, and Grade 4 glioblastoma in 5 patients. As postoperative
adjuvant therapy, 4 patients received irradiation in combination with temozolomide (TMZ)
and 2 patients received irradiation and ACNU-based multidrug chemotherapy.
3. Methods
3.1. Talaporfin sodium and diode laser
Talaporfin  sodium  (TS:  Laserphyrin®,  Meiji  Seika  Pharma  Co.,  Ltd.,  Tokyo,  Japan)  is  a
photosensitizer  utilized  in  PDT which  was  approved for  use  in  Japan in  2003  as  treat‐
ment for early-stage lung cancer, in conjunction with a diode laser (PD Laser®, Panasonic
HealthCare Co., Ltd., Ehime, Japan) at a wavelength of 664 nm [4]. (Fig. 1A and B) Tala‐
porfin sodium is a second-generation photosensitizer which is more quickly excreted from
the body than the first-generation porfimer sodium (Photofrin®,  Pfizer  Japan Inc.,Tokyo,
Japan). It is characterized by the rapid resolution of a skin photosensitive reaction, which
is  important  with  the  use  of  photosensitizers.  This  has  enabled the  period of  necessary
light shielding in a room with measurement of < 500 lux to be reduced to 2 weeks for ta‐
laporfin sodium, whereas porfimer sodium requires patients to stay in a semi-dark(< 300
lux) room for 1 month after administration. The diode laser instrument is a compact sys‐
tem weighing 14 kg, has low power consumption, and can be easily maintained without
the need for dye exchange. (Fig. 2A).
3.2. Operating microscope equipped with diode laser
The PD Laser® (Panasonic HealthCare Co., Ltd.), installed in the MM30 microscope (Mitaka
Kohki Co., Ltd., Tokyo, Japan), is combined into a system which provides laser irradiation
from the operating microscope from a plane nearly coaxial to the surgical view. The laser is
introduced into the microscope by a quartz fiber, and providing a laser transmission path
close to an observation light path using a conventional halogen light. This allows surgeons
to accurately identify an irradiation target area during surgery. (Fig. 2A, B)
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Figure 1. Second-generation photosensitizer, Talaporfin sodium. A:Chemical structures of talaporfin sodium (mono-L-
aspartyl chlorine e6, NPe6) N-[[(2S,3S)-18-carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dibydro-3,7,12,17-tetramethyl-8-vi‐
nylporphyrin-20-yl]-L-asparatic acid. B:Absorption spectrum of talaporfin sodium and change in absorption
wavelength following conjugation with albumin (solid line; talaporfin sodium and phosphate buffer solution, dotted
line; talaporfin sodium conjugated with albumin) talaporfin sodium has absorption peaks in the Soret band (398nm)
and Q bands (502, 530, 620 and 654nm) in pH 7.4 phosphate buffer solution (PBS). When it conjugates with albumin,
its absorption band wavelength becomes approximately 10nm longer (bathochromic shift).





Figure 2. Diode laser with a neurosurgical operating microscope. A: MM80® microscope (Mitaka Kohki Co., Ltd.)
equipped with a compact-size diode laser (PD Laser®, Panasonic Health Care Ltd., arrow). B: From the operating micro‐
scope, the diode laser irradiates the surgical field with an irradiation diameter of 1.5 cm2.
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3.3. Photodynamic therapy (PDT)
TS was administered bolus intravenously at a dose of 40mg/m2 in shielded conditions 24
hours prior to surgery. At surgery, maximal resection of the tumor was performed usually
utilizing optical navigation system and electrophysiological monitoring leaving a tumor bed
area to be irradiated. The surface area of tumor bed was observed under operative micro‐
scope and optimal navigation system, and identified the optimal target for PDT. PDT cover‐
ing an area of 1.5 cm2 diameter was used for any tumor growth in these area. When 2 sites
were to be irradiated, we took care to avoid overlapping the irradiated areas under opera‐
tive microscope. Irradiation energy density of 27 J/cm2 (power density of 150mW/cm2, irradi‐
ation time of 180 seconds) of 664nm diode laser for PDT was irradiated superficially to one
or two targets of tumor bed.
3.4. Skin photosensitive reaction test
The administration of TS enhances sensitivity to light, and which may produce a photosen‐
sitive reaction. Patients should therefore avoid direct sunlight immediately after the admin‐
istration of talaporfin sodium and stay in a room where the illumination intensity is
adjusted to < 500 lux using a shading curtain. After surgery, patients were required to ex‐
pose the back of the palm of the hand to direct sunlight for 5minutes every day between
11:00 and 14:00 to evaluate the development of erythema. However, even when the result of
this skin photosensitivity test confirmed the resolution of a photosensitive reaction (defined
by the absence of evident erythema) and the restriction for shading at < 500 lux could be re‐
moved, patients were advised to avoid further direct sunlight for 2 weeks after the adminis‐
tration of talaporfin sodium. In particular, we recommended that special shading eye
goggles should be used worn 7 days after the administration of talaporfin sodium to avoid
exposing the retinas to direct sunlight.
4. Results
4.1. Selected case
A 65-year-old man presented with 2 months history of headache and gradually worsened.
Head MRI showed a tumor in the right frontal lobe, and edema extending as far as the pre-
motor area at the posterior edge of the tumor bulk. On a sagittal view, part of the posterior
edge of the tumor bulk extended posteriorly, and this part was determined to have invaded
the supplemental motor area(SMA) (Fig. 3A and B). Using optical navigation system and
motor evoked potential (MEP) monioring, we performed craniotomy in order to resect the
tumor, and rapid pathological diagnosis confirmed that the tumor was a glioblastoma. From
the optical navigation images, the posterior margin of the tumor bulk was confirmed to
have reached the pre-motor area (SMA-proper) (Fig.3C), and a single session of PDT at 27
J/cm2 (diameter of the irradiated area: 1.5 cm2) was performed at this site (Fig 3.D and E).
Under a pathological diagnosis of glioblastoma, the patient given postoperative irradiation
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and chemotherapy with oral TMZ. On day 3 after surgery, MRI showed remaining contrast-
enhanced tumor growth in the pre-motor area, but by the end of radiotherapy (on day 51
after surgery, Fig. 3F), complete response was confirmed at this site. His headache was dis‐
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Figure 3. PDT and changes over time on postoperative magnetic resonance imaging (MRI) in Case 3. A: Preoperative
axial FLAIR image showed the right frontal tumor and the peri-tumoral edema extending to the right pre-motor cor‐
tex. B: Preoperative gadolinium-enhanced T1-weighted sagittal imaging showed a heterogeneously enhanced tumor
was present in the right superior frontal gyrus to supplementary motor cortex. C: Based on intra-operative optical nav‐
igation images, it was determined that the tumor had reached a portion adjacent to the ambulatory motor area
(green cross). D: The tumor was remained in this area (arrow). E: PDT at 150 mW/cm2 and 27 J/cm2 (diameter of the
irradiation area: 1.5 cm2) was performed for tumor infiltration into this area. (aluminum foil protected the anterior
cerebral arteries, arrow). F: Gadolinium-enhanced T1-weighted sagittal imaging on days 51 after surgery showed that
gadolinium-enhancement at the site of PDT had disappeared.




In the evaluation of patients, of the 6 patients who were assessable after surgery, 3 achieved
complete response, 2 achieved partial response, and 1 had progressive disease. The response
rate was high at 83.3%. Regarding adverse events associated with PDT, brain edema involv‐
ing a large part of the middle cerebral artery perforator region occurred during PDT after
insular glioma resection in Case 1. While it remains uncertain whether this was associated
with the surgical procedure or PDT, the effect on normal capillary vessels should be closely
monitored. No other obvious adverse events were observed. In most patients, postoperative
chemo-radiation therapy was initiated, but recurrence was observed at the site of PDT in 7
patients. Despite recurrence, the progression-free survival time was 1 to 34 months (median:
22 months), and in cases receiving treatment after recurrence, 5 patients had a survival time
of 6 to 14 months (median: 6 months). A further 3 patients of Grade 3 were alive during a
follow-up period of 42 to 74 months (median: 50 months). An evaluation of 5 patients with
glioblastoma also showed a median progression-free survival time of 14 months and a me‐
dian survival time of 26 months.
While it was possibly an adverse event associated with the surgical procedure, a causal rela‐
tionship with the PDT could not be excluded. In terms of photosensitivity, the photosensi‐
tive reaction resolved within 3 days after surgery (within 4 days after the intravenous
injection) in all patients, at which point light shading at 500 lux was discontinued.
5. Discussion
The objective of PDT is to selectively kill infiltrating tumor cells via a photochemical reac‐
tion, and this selectivity facilitates optimal local control therapy [2], making it possible to
maintain brain function. PDT is designed to cause damage at the cellular level in the form of
apoptosis [2]. There are numerous studies which have reported that the main mechanism of
PDT is the induction of vascular occlusion from fibrin thrombus formation due to vascular
endothelial cell damage [5]. In particular, it has been assumed that the main mechanism on
cellular damage induced by PDT using TS in conjunction with a diode laser irradiation is
indirect damage in the form of coagulation necrosis by tumor vascular occlusion [5]. In our
basic experimental study, C6 glioma tissue showed coagulation necrosis in tissues located in
a portion near the tumor surface that was laser irradiated, and cellular death in the distal
portion [3]. However, in the actual area of tissue damage, 80% of the area was considered to
be tissue damage caused by the coagulation necrosis. Yamamoto et al. [5] reported that fac‐
tor XIII was activated by vascular endothelial cell damage within 20 seconds following PDT
of cancer tissue. A fibrin thrombus formed as a consequence, which appeared to be the main
mechanism of PDT.
Our strategy was to optimally reduce vascular damage caused by PDT, and to ensure safety
to avoid ischemic damage to normal brain tissues. Madsen et al. [6] reported that the factors
which influence the effects of PDT were tissue factors and irradiation laser factors. The tis‐
sue factors included the tissue concentrations of the photosensitizer, the level of tissue oxy‐
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genation, and the depth from the site of laser irradiation. The irradiation laser factors
included irradiation level and duration. How the cytotoxic effects can be enhanced while
minimizing the vascular effects, and how ischemic damage to normal brain tissues can be
minimized may well be the keys to determining whether or not PDT can be developed for
the treatment of malignant glioma.
In the present study, we selected a dose of 40 mg/m2 of TS and performed PDT approxi‐
mately 24 hours after the administration of TS. The practice of the PDT was performed on
the diode laser (664nm) irradiation at a power density of 150 mW/cm2 for 180 seconds (27
J/cm2). We previously reported that this PDT protocol was considered safe in terms of the
protection of early vascular endothelial cell damage and normal brain tissues, and could in‐
duce the selective tumor cell damage by singlet oxygen [7].
Although there were only consecutive 8 patients of newly diagnosed malignant glioma in
this series, PDT achieved a response rate of 83.3% and a median progression-free survival
time of 14 months, a median survival time of 26 months in the glioblastoma patients who
eventually died, and all 3 cases of Grade 3 patients were survived for 50 months median fol‐
low up period. In the 5 patients who achieved complete or partial response, preoperative
KPS was improved. None of the patients had adverse events unequivocally attributable to
PDT. The brain edema observed in Case 1 was possibly due to the surgical procedure, but
the possibility of direct laser irradiation of brain blood vessels inducing vascular occlusion
due to PDT could not be completely excluded. Therefore, normal blood vessels should be
covered with aluminum foil whenever possible.
Response RTx Chemo Tx KPS aftertreatment Progression PFS
Prognosis, Survival
period
NE 60Gy ACNU/VCR/IFN 50 (+) 22 mon. Dead: 36 mon.
CR 60Gy IFN 70 (+) 24 mon. Alive: 74 mon.
CR 60Gy TMZ 90 (+) 34 mon. Dead: 40 mon.
PR 60Gy TMZ 90 (+) 14 mon. Dead: 26 mon.
PR 60Gy (-) 50 (+) 24 mon. Alive: 50 mon.
PD (-) TMZ 40 (+) 1 mon. Dead: 7 mon.
CR 60Gy PCZ/ACNU/VCR 80 (+) 6mon. Dead: 12mon.
NE 60Gy TMZ 90 (-) Alive: 42mon.
KPS: Karnofsky Performance Scale, PDT: photodynamic therapy, RTx: radiation therapy, Chemo Tx: chemo‐
therapy, PFS: progression-free survival, Rt: right, Lt: left, Bil: bilateral, Anapl: anaplastic, CR: complete re‐
sponse, PR: partial response, PD: progression disease, NE: not evaluable, TMZ: temozolomide, VCR:
vincristine, IFN: interferon-beta, PCZ: procarbazine, mon. months
Table 1. Clinical summary of patients with newly diagnosed malignant glioma who received photodynamic therapy
(PDT)
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The present study of PDT using talaporfin sodium in conjunction with diode laser irradiation
for malignant glioma supports the validity of PDT for malignant glioma in Japan. Laser irra‐
diation used to activate TS has a longer wavelength (664 nm) than that used with other photo‐
sensitizers,  such  as  Porfimer  sodium  [8-11],  5-ALA  [12-14]  and  m-THPC  [15,  16],  and
theoretically, it can penetrate brain tissue to a greater depth. We believe that our strategy will
demonstrate a therapeutic effect not to be inferior to those of previous reports [17] using other
photosensitizers.  In future, it  is necessary to perform the larger-scale prospective clinical
study to confirm the clinical feasibility of this novel therapeutic option to malignant gliomas.
6. Conclusions
We performed PDT using TS in conjunction with diode laser irradiation in areas of tumor
invasion, following resection of adult malignant glioma which had infiltrated the eloquent
areas. We selected a 24 hours interval after the administration of TS before commencing
PDT and reduced irradiation energy intensity of the diode laser to 27 J/cm2 to preserve nor‐
mal brain function. The therapy achieved with no adversed event directly attributable to
PDT and a response rate of 83.3% in patients with a newly diagnosed malignant gliomas.
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